Screener
Crinetics Pharmaceuticals CRNX Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2025
- Accession
- 0001658247-26-000012
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Other expense, net | (357) | (519) | (159) |
| Total other income, net | 51,632 | 40,916 | 13,277 |
| Loss before income taxes | (465,137) | (297,938) | (209,331) |
| Income tax expense | 180 | — | — |
| Loss before equity method investment | (465,317) | (297,938) | (209,331) |
| Loss on equity method investment | — | (470) | (5,198) |
| Net loss | $(465,317) | $(298,408) | $(214,529) |
| Net loss per share: |
Item 16. Form 10-K Summary
FAQ
- What is Crinetics Pharmaceuticals's income tax?
- Crinetics Pharmaceuticals (CRNX) reported income tax of $45K in Q4 2025.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Crinetics Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude